Education
About Us
Working with TipRanks
Follow Us
Revelation Biosciences (REVB)
NASDAQ:REVB
REVB Stock Chart & Stats
$0.86
-$0.04(-6.62%)
At close: 4:00 PM EST
$0.86
-$0.04(-6.62%)
Day’s Range― - ―
52-Week Range$0.83 - $60.48
Previous CloseN/A
Volume326.26K
Average Volume (3M)740.56K
Market Cap
$5.08M
Enterprise Value-$3.37M
Total Cash (Recent Filing)$12.71M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Mar 26, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.77
Shares Outstanding5,924,137
10 Day Avg. Volume239,834
30 Day Avg. Volume740,557
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.81
Price to Sales (P/S)0.00
P/FCF Ratio-0.21
Enterprise Value/Market Cap-0.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.41
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Revelation Biosciences News
REVB FAQ
What was Revelation Biosciences’s price range in the past 12 months?
Revelation Biosciences lowest stock price was $0.83 and its highest was $60.48 in the past 12 months.
What is Revelation Biosciences’s market cap?
Revelation Biosciences’s market cap is $5.08M.
When is Revelation Biosciences’s upcoming earnings report date?
Revelation Biosciences’s upcoming earnings report date is Mar 26, 2026 which is in 92 days.
How were Revelation Biosciences’s earnings last quarter?
Revelation Biosciences released its earnings results on Nov 06, 2025. The company reported -$1.77 earnings per share for the quarter, missing the consensus estimate of -$1.695 by -$0.075.
Is Revelation Biosciences overvalued?
According to Wall Street analysts Revelation Biosciences’s price is currently Overvalued.
Does Revelation Biosciences pay dividends?
Revelation Biosciences does not currently pay dividends.
What is Revelation Biosciences’s EPS estimate?
Revelation Biosciences’s EPS estimate is -0.33.
How many shares outstanding does Revelation Biosciences have?
Revelation Biosciences has 5,924,137 shares outstanding.
What happened to Revelation Biosciences’s price movement after its last earnings report?
Revelation Biosciences reported an EPS of -$1.77 in its last earnings report, missing expectations of -$1.695. Following the earnings report the stock price went down -2.97%.
Which hedge fund is a major shareholder of Revelation Biosciences?
Currently, no hedge funds are holding shares in REVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Revelation Biosciences
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
Technical Analysis
GT Biopharma
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
Azitra Inc
―
Ownership Overview
14.50% Insiders
0.02% Mutual Funds
6.15% Other Institutional Investors
79.33% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---